Shattuck Labs, Inc.
7 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study of SL-325 in Crohn's Disease Patients (NCT07753850) | Shattuck Labs, Inc. | 2026-10-01 |
| Phase 1 Study of SL-325 in Healthy Volunteers (NCT07158437) | Shattuck Labs, Inc. | 2025-09-18 |
| Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (NCT05483933) | Shattuck Labs, Inc. | 2022-08-18 |
| Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (NCT05275439) | Shattuck Labs, Inc. | 2022-03-17 |
| Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin (NCT04502888) | Shattuck Labs, Inc. | 2020-09-17 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618) | Shattuck Labs, Inc. | 2019-03-26 |
Track Shattuck Labs, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.